Introduction {#Sec1}
============

Intra-arterial radioembolisation with yttrium-90 microspheres (^90^Y-MS), either resin-based or with a glass matrix, is an increasingly applied treatment for patients with unresectable liver malignancies \[[@CR1], [@CR2]\]. Efficacy of ^90^Y radioembolisation relies on the difference in blood supply between liver malignancies and the normal liver parenchyma, which is predominantly arterial and mainly portal, respectively \[[@CR3], [@CR4]\]. This allows for the ^90^Y-MS, when instilled into the hepatic artery, to target the tumours, consequently delivering high tumour absorbed doses whilst largely sparing the non-tumour-bearing liver tissue \[[@CR1]\]. A critical component is the pretreatment procedure which consists of coeliac and superior mesenteric angiography and selective coiling of arteries supplying non-target organs such as the gastroduodenal artery and the right gastric artery, to ensure that the dose of ^90^Y-MS is implanted exclusively into the liver. To assess whether the coiling has been performed appropriately, technetium-99m albumin macroaggregates (^99m^Tc-MAA) are injected into the hepatic artery. Subsequently, nuclear imaging is performed to determine whether extrahepatic deposition of the ^90^Y-MS should be expected and to calculate the lung-shunt fraction \[[@CR5]--[@CR7]\]. The images are also used to predict the intrahepatic distribution of the ^90^Y-MS or, more specifically, the tumour-to-normal tissue ratio \[[@CR8]--[@CR10]\]. The ^99m^Tc-MAA are thus deployed as full surrogates for the ^90^Y-MS. However, there are indications that this assumption is not justified as the reality is that the ^99m^Tc-MAA image does not in all cases accurately correspond with the post-^90^Y-MS infusion bremsstrahlung image. This is caused by differences in resolution between these images and also due to the overt differences in physical characteristics and in numbers of particles infused between the ^99m^Tc-MAA and the ^90^Y-MS \[[@CR11], [@CR12]\] (Table [1](#Tab1){ref-type="table"}). It has been demonstrated clinically that the intrahepatic uptake pattern of ^99m^Tc-MAA is not a strong predictor of tumour response after ^90^Y radioembolisation \[[@CR13]\]. Table 1Characteristics of the microparticles SIR-Spheres (SIRTeX Medical Ltd.)TheraSphere (MDS Nordion Inc.)^99m^Tc-MAA (Technescan® LyoMAA, Mallinckrodt Medical Inc.)^166^Ho-PLLA-MS (UMC Utrecht)Radionuclide^90^Y^99m^Tc^166^Hoβ^−^emission (MeV)2.28 (100%)No β emission1.77 (49%)1.85 (50%)γ emission (keV)No γ emission141 keV (89%)80.6 (6.7%)Matrix materialResinGlassAggregated human serum albuminPLLADensity (g/ml)1.6 \[[@CR29]\]3.2 \[[@CR29]\]1.1 \[[@CR30]\]1.4Diameter (μm)32 ± 10 \[[@CR29]\]25 ± 10 \[[@CR29]\]10--60 \[[@CR11]\]30 ± 5Administered number of particles50,000,000 \[[@CR7]\]4,000,000 \[[@CR7]\]150,000 \[[@CR11]\]33,000,000

Post-administration visualisation of the ^90^Y-MS is thus possible through bremsstrahlung single photon emission computed tomography (SPECT) imaging, but the quality is poor \[[@CR14], [@CR15]\]. To overcome this lack of adequate visualisation, poly([L]{.smallcaps}-lactic acid) microspheres loaded with holmium-166 (^166^Ho-PLLA-MS) have been developed \[[@CR16]--[@CR19]\]. Like ^90^Y, ^166^Ho is a high-energy beta-emitter, but it emits low-energy gamma photons as well (Table [1](#Tab1){ref-type="table"}), allowing for quantitative SPECT analysis and consequently dosimetric analysis \[[@CR20]\]. Because holmium is also highly paramagnetic, the (intrahepatic) distribution of the ^166^Ho-PLLA-MS can be assessed through magnetic resonance imaging (MRI) as well \[[@CR21], [@CR22]\]. In addition, instead of ^99m^Tc-MAA, a small scout dose of ^166^Ho-PLLA-MS could be utilised to predict the biodistribution of the treatment dose of ^166^Ho-PLLA-MS.

In this article, the concept of a small scout dose of ^166^Ho-PLLA-MS employed to predict the biodistribution of the therapeutic dose of ^166^Ho-PLLA-MS is investigated in the porcine model. The applicability of multimodal imaging (gamma scintigraphy, X-ray computed tomography (CT) and MRI) is also investigated. The accuracy of quantitative ^166^Ho SPECT analysis for heterogeneous distribution is also validated.

Materials and methods {#Sec2}
=====================

Animals {#Sec3}
-------

Five healthy female pigs (8--9 months old, weighing 70--75 kg) were acquired from the Animal Sciences Group, Wageningen University and Research Centre, Lelystad, the Netherlands. A 2-week acclimatisation period was allowed. The experiments were conducted in agreement with the local applicable Dutch law, "Wet op de dierproeven" (art. 9) (1977), and the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes (1986), and approved by the ethics committee for animal experimentation of the University Medical Centre Utrecht, Utrecht, the Netherlands (DEC-ABC-no. 2007.III.07.092).

Microsphere preparation {#Sec4}
-----------------------

^165^Ho-PLLA-MS were prepared as previously described \[[@CR17]\] (scout dose 60 mg; 'treatment dose' 540 mg) and packed in custom-made high-density polyethylene (HDPE) vials (Fig. [1](#Fig1){ref-type="fig"}) and neutron activated in the nuclear reactor of the Delft University of Technology (Delft, the Netherlands). Upon delivery at the hospital, two incompletely predrilled holes in the vial cover were perforated by needles (19 G × 50 mm), and the microspheres were suspended in 2 ml of water for injection containing 2% Pluronic® F-68 (Sigma-Aldrich Chemie B.V., Zwijndrecht, the Netherlands) and 10% absolute ethanol (Merck B.V., Amsterdam, the Netherlands). The cover of the vial was then removed and a tiny amount of ^166^Ho-PLLA-MS (ca. 1 mg) was taken out for quality control (by light microscopy) \[[@CR23]\]. Next, a vial cover fitted with a PTFE/silicone septum (Sigma-Aldrich Chemie B.V., Zwijndrecht, the Netherlands) was screwed on top of the vial which was punctured by two needles (19 G × 50 mm). The amounts of radioactivity were measured in a dose calibrator (VDC-404, Veenstra Instrumenten B.V., Joure, the Netherlands). In order to prevent pile up and dead-time effects in the gamma camera, both the scout dose and the treatment dose consisted of 250 MBq ^166^Ho at the time of injection. Fig. 1Schematic of the custom-made administration system for clinical application, which consists of the following components: iodine contrast agent (*1*), saline solution (*2*), 20-ml syringe (Luer-Lock) (*3*), three-stopcock manifold (*4*), one-way valve (*5*), inlet line (*6*), administration vial containing the ^166^Ho-PLLA-MS (*7*), outlet line (*8*), flushing line (*9*), Y-connector (*10*) and catheter (*11*). Not shown in this diagram is the lead-glass vial shield in which the HDPE vial is placed to limit the radiation dose to which the personnel are exposed

Anaesthesia and analgesia {#Sec5}
-------------------------

Premedication consisted of azaperone (4 mg/kg), ketamine hydrochloride (10 mg/kg) and atropine (0.1 mg/10 kg) intramuscular (IM). General anaesthesia was induced by intravenous administration (IV) of propofol (2.5--3.5 mg/kg) and maintained by propofol (8--9 mg/kg/h) or inhalation of isoflurane (1.5--2.0%) in O~2~/air (1:1), in combination with midazolam hydrochloride (0.2 mg/kg) IV. Perioperative analgesia was provided by sufentanil (loading dose 5 μg/kg, maintenance dose 10 μg/kg/h) IV.

Administration system {#Sec6}
---------------------

A custom-made administration system was used (Fig. [1](#Fig1){ref-type="fig"}) that consisted of polyethylene tube lines equipped with one-way valves (Medisize B.V., Hillegom, the Netherlands) preventing backflow of microspheres in the lines. The lines were interconnected using a Y-connector (World Precision Instruments Inc., Sarasota, FL, USA). The system was connected to the catheter. To reduce the radiation dose to personnel the vial containing the ^166^Ho-PLLA-MS was placed in a high-density lead-glass vial shield.

Angiography and microsphere administration procedure {#Sec7}
----------------------------------------------------

A right femoral artery puncture was made and an Avanti® + sheath (7F, Cordis Europe N.V., Roden, the Netherlands) was introduced. Under fluoroscopic guidance, the common hepatic artery was catheterised and the exact anatomy of its branches was mapped out. Standard diagnostic 4F catheters and guide wires were used. The scout dose and treatment dose of ^166^Ho-PLLA-MS were flushed out of the vial and into the (straight tip) catheter, positioned in the proper hepatic artery, by injecting 40--60 ml of a 50:50 mixture of saline and iodine contrast agent into the vial, under fluoroscopy guidance, at a rate of 0.5--1.0 ml/s.

Medical imaging protocols {#Sec8}
-------------------------

For registration purposes, multimodal markers, filled with 2 MBq ^99m^Tc each, were attached to the skin just cranially and caudally from the liver. In vivo planar nuclear imaging and SPECT imaging were performed directly after administration of the scout dose and after administration of the treatment dose. The nuclear images were acquired and the SPECT images reconstructed as was previously described \[[@CR20]\]. CT was performed after the treatment dose was administered (tube voltage 120 kVp, current 400 mAs; Brilliance®, Philips Healthcare, Best, the Netherlands). After termination with sodium pentobarbitone (100--200 mg/kg) IV, MRI was performed, including *T*~1~, *T*~2~ and *T*~2~\* protocols, using a 1.5-T clinical device (Achieva®, Philips Healthcare, Best, the Netherlands), according to previously described protocols \[[@CR22]\].

SPECT analysis {#Sec9}
--------------

The distributions of the scout dose and of the 'total dose' (scout dose + treatment dose) were compared. After rigid registration and downsampling to a 32 × 32 × 32 matrix (18.9-mm voxel size), scatter plots were generated of which regression analysis was done. The accuracy of quantitative SPECT was assessed in a realistic model, by comparing the distribution of a SPECT image with the planar images of a pig's liver, in which ^166^Ho-PLLA-MS (600 mg, 250 MBq at time of acquisition) had been injected into the hepatic artery ex vivo. The liver was placed in a metal box, in which five 16-mm-diameter tubes were also placed. The box was filled with carboxymethyl cellulose (CMC) (2.5%) and subsequently frozen at −20°C. Twenty-four hours later the tubes were removed and the remaining holes were filled with a ^166^Ho/CMC chloride solution as radioactive markers. The box was again placed in the freezer. After SPECT acquisition, the liver was cut into eight 6-mm-thick slices with a floor-model band saw and planar nuclear images were acquired of each slice. The planar images were combined into a 3D volume, which was registered to the SPECT image and resampled to the same (isotropic) voxel size, after which scatter plot analysis was performed. The markers were used for registration and normalisation of the slices.

Results {#Sec10}
=======

Angiography and microsphere administration procedure {#Sec11}
----------------------------------------------------

Selective catheterisation of the hepatic artery was successfully performed in all five pigs. The ^166^Ho-PLLA-MS were gradually flushed out of the administration vial in a controlled manner. Y-connectors of a diameter matching that of the tube lines were used which prevented lodging of the ^166^Ho-PLLA-MS in the system. Measurements showed that less than 1% of the radioactivity remained in the administration systems used in any of these experiments.

SPECT analysis {#Sec12}
--------------

Visual analysis of the SPECT images revealed that in all animals the ^166^Ho-PLLA-MS had been deposited in the liver exclusively. Qualitatively, the intrahepatic radioactivity distributions according to the respective scout dose and 'total dose' images of four out of five animals seemed similar (Fig. [2](#Fig2){ref-type="fig"}a--h). This was not the case for the images of the fifth animal, which was caused by unintended catheter displacement between the administration of the scout dose and the treatment dose (Fig. [2](#Fig2){ref-type="fig"}i,j). Rigid registration and subsequent analysis of the SPECT images of the scout dose and total dose was feasible in two out of five animals. In one of these animals (the one in which the catheter was displaced between administrations) the relation between the scout dose distribution and total dose distribution was rather poor (*r*^2^ = 0.34), whereas in the other animal the relation was significantly better (*r*^2^ = 0.66) (Fig. [3](#Fig3){ref-type="fig"}). Fig. 2Planar nuclear images (anterior view) of the pigs acquired after administration into the hepatic artery of the scout dose of ^166^Ho-PLLA-MS (60 mg, 250 MBq) (**a**, **c**, **e**, **g**, **i**), and planar nuclear images acquired from the total dose, which constitutes the scout dose and the subsequently administered 'treatment dose' of ^166^Ho-PLLA-MS (540 mg, 250 MBq) (**b**, **d**, **f**, **h**, **j**)Fig. 3Scatter plots obtained from the SPECT images of two pigs, in which the distribution of the respective scout dose and total dose were compared. In one animal the relation between the scout dose and the total dose was quite good (**a**), whereas in the other animal the relation between the scout dose and the total dose was rather poor (**b**)

Comparison by scatter plot analysis of planar nuclear images of slices of the ex vivo pig liver, combined into a 3D volume, with the SPECT image revealed a strong correlation between the SPECT and the planar images (*r*^2^ = 0.90) (Fig. [4](#Fig4){ref-type="fig"}). Fig. 4Maximum intensity projections of the stacked planar nuclear images acquired from an ex vivo pig liver (**a**) and of the SPECT image of this liver (**b**). Quantification of the SPECT images using hybrid scatter correction demonstrated that the radioactivity distribution according to the SPECT images was highly similar to the distribution based on the planar images (**c**)

CT and MRI {#Sec13}
----------

Relatively high concentrations of ^166^Ho-PLLA-MS present in hepatic arteries could be visualised by CT (Fig. [5](#Fig5){ref-type="fig"}a) Holmium-based artefacts could be observed on the *T*~2~\*-weighted MR images (Fig. [5](#Fig5){ref-type="fig"}b). The distribution of ^166^Ho-PLLA-MS observed on the MR images was quite similar to CT. A discrepancy was seen in liver regions containing lower concentrations of ^166^Ho-PLLA-MS. Relatively low concentrations still detectable by MRI were absent on the CT images. Fig. 5^166^Ho-PLLA-MS visualised by CT maximum intensity projection (**a**), and by *T*~2~\*-weighted MRI (8-mm slice) (**b**). High concentrations are indicated by *circles*

Discussion {#Sec14}
==========

The characteristics of ^166^Ho-PLLA-MS could enable the use of a scout dose of ^166^Ho-PLLA-MS to predict the distribution of the therapeutic dose of ^166^Ho-PLLA-MS. In this study, this concept has been tested in a relatively anthropomorphic animal model, namely the domestic pig. Five pigs were successfully catheterised and a scout dose and a treatment dose were injected into the hepatic artery. The use of the dedicated neutron-activation/administration vial made pretreatment quality control of the ^166^Ho-PLLA-MS possible and prevented the need to transfer radioactivity from a neutron activation vial to an administration vial. The tube lines in the systems supplied by the manufacturers of the glass and resin microspheres are connected using standard three-way stopcocks. It is reported that ^90^Y-MS tend to be retained in and just before the stopcock \[[@CR24]\]. Loosening up the jammed microspheres requires tapping and/or gently shaking of the stopcock. In the presently used system this lodging of microspheres did not occur because, instead of stopcocks, Y-connectors of a diameter matching that of the tube lines were used. Administration of the ^166^Ho-PLLA-MS suspended in a mixture of saline and iodine contrast agent permitted immediate observation of stasis and/or backflow and timely interruption of the procedure.

Preclinical research has also been conducted by other groups on the development of microspheres that mimic ^90^Y-MS better than the ^99m^Tc-MAA, and which, like ^166^Ho-PLLA-MS, possess high quality imaging possibilities. Recently proposed substitutes for the glass ^90^Y-MS were iron-labelled glass-ceramic microspheres \[[@CR12]\]. In Vx2 carcinoma-bearing rabbits, it was demonstrated that these iron-labelled particles can be visualised in real time by MRI. Resin microspheres labelled with fluorine-18 (^18^F) allowing for positron emission tomography were proposed to serve as surrogates for the resin ^90^Y-MS \[[@CR25]\]. These ^18^F microspheres may also enable accurate assessment of the biodistribution of the treatment dose when co-injected with the resin ^90^Y-MS. Regarding both the iron-labelled glass-ceramic microspheres and the ^18^F resin microspheres, extensive preclinical research is warranted before clinical application will be allowed.

^166^Ho is a true multimodal agent, allowing for visualisation by gamma scintigraphy, MRI and CT. The sensitivity of CT for holmium is relatively low; compared with SPECT its sensitivity is 2--3 orders of magnitude lower, and approximately 20 times lower than that of MRI \[[@CR26]\]. It is therefore expected that CT is too insensitive to allow reliable biodistribution assessment of a scout dose of 60 mg of ^166^Ho-PLLA-MS. MRI was able to detect ^166^Ho-PLLA-MS at lower concentrations than CT, which was supported by previously reported results \[[@CR26], [@CR27]\]. As MRI provides detailed anatomic imaging as well, this technique is thought to be especially useful in dynamic imaging of ^166^Ho-PLLA-MS accumulating in and around tumours, and could provide real-time monitored (supra)selective administration of ^166^Ho-PLLA-MS \[[@CR28]\]. For its high sensitivity SPECT is currently the best-suited imaging technique for visualisation of both the scout dose and the treatment dose of ^166^Ho-PLLA-MS. For safety and efficacy purposes individualised dose calculation is required. To this end pretreatment tumour and liver dosimetry is a prerequisite. Dosimetry entails quantitative SPECT analysis which was validated for a distinctly inhomogeneous distribution of ^166^Ho-PLLA-MS in this study. The methodology described in this paper is aimed at improving clinical results of radioembolisation in patients with unresectable liver tumours. Confirmation of the clinical applicability of this concept has to be established in upcoming patient studies.

Conclusions {#Sec15}
===========

In non-tumour-bearing pigs, a scout dose of ^166^Ho-PLLA-MS can accurately predict the biodistribution of a treatment dose of ^166^Ho-PLLA-MS, as assessed by qualitative and quantitative SPECT. MRI can accurately visualise low concentrations of ^166^Ho-PLLA-MS. Quantitative ^166^Ho SPECT, necessary for dosimetric analysis, was validated in a realistic model. The custom-made administration system and neutron-activation/administration vial was tested as well and found satisfactory for the neutron activation and the administration of ^166^Ho-PLLA-MS.
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